No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Approves UCB’s 320mg Single-Injection Device Presentations of Bimzelx® (Bimekizumab)
On 14 October 2024, UCB announced that the US FDA has approved a 2 mL pre-filled syringe and pre-filled autoinjector, each containing 320 mg of Bimzelx® (bimekizumab-bkzx), adding to the already approved 1 ml (160 mg) device presentation. On 23 September 2024, UCB...